Evidence map›Paper›PMID 41770326›Full record

ArticleInnere Medizin (Heidelberg, Germany)2026

[Tobacco and nicotine prevention-Safeguarding the future of Germany].

Stefan Andreas, Christian Taube, Claus Vogelmeier, Natascha Sommer

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stefan AndreasG-BA Lungenzentrum (Hessen), Deutsches Zentrum für Lungenforschung (DZL), Lungenfachklinik Immenhausen, Immenhausen, Deutschland.
Christian TaubeKlinik für Innere Medizin mit Schwerpunkt Pneumologie, Intensiv- und Schlafmedizin, Mitglied des Deutschen Zentrums für Lungenforschung (DZL), Universitätsklinikum Gießen und Marburg (UKGM), Standort Marburg, Marburg, Deutschland.
Claus VogelmeierKlinik für Pneumologie, Universitätsmedizin Essen, Ruhrlandklinik, Essen, Deutschland.
Natascha SommerMedizinische Klinik II, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Mitglied des Deutschen Zentrums für Lungenforschung (DZL), Institut für Lungengesundheit (ILH), Justus-Liebig-Universität Gießen, Aulweg 130, 35392, Gießen, Deutschland. natascha.sommer@innere.med.uni-giessen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tobacco smoking is still one of the most important avoidable risk factors for early morbidity and mortality. Smokers lose roughly one decade of life, whereas the cessation of smoking leads to an increase in the quality of life and years of life. In Germany the life expectation is disproportionately low in view of the well-developed social security system and the number of heathy years is reduced in the younger generations. An essential reason is considered to be the previous focus on curative instead of preventive medicine, among others caused by the lack of a superordinate strategy for prevention. In the past measures for individual prevention were shown to be less effective than measures for behavioral prevention, such as tobacco tax and smoking bans. The cessation of smoking is an essential component of secondary prevention but is currently insufficiently promoted and implemented by those responsible in the healthcare system and is additionally poorly funded. New products containing nicotine are infiltrating the market, which among other things are unsuitable for smoking cessation due to the high potential for dependency and the cardiovascular and pulmonary risk profiles. Additional measures, such as the limitation of the influence by the tobacco industry, the implementation of the "Strategy for a tobacco-free Germany 2040" and the complete remuneration of costs for tobacco cessation are necessary in the future to fulfil the minimum standard for prevention, to sustainably reduce the foreseeable cost explosion in the healthcare system and to enable a sustainable society.

Indexed as

Smoking CessationSmoking PreventionTobacco Use DisorderForecastingGermanyHumansNicotineSmokingNicotineBehavioral preventionElectronic cigarettesStructural preventionTobacco cessationTobacco industry

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.